Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.70 |
| ▸ | MMP9 | P14780 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | GHSR | Q92847 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7995079 | 1.00 | MMP2 (0.70) | MMP2MMP9ALDH1A1HTTGHSR | |
| SCHEMBL4653160 | 0.96 | MMP2 (0.76) | MMP2MMP9ALDH1A1HTTGHSR | |
| SCHEMBL1750430 | 0.96 | MMP2 (0.76) | MMP2MMP9ALDH1A1HTTGHSR | |
| SCHEMBL1385016 | 0.91 | ALDH1A1 (0.72) | MMP2MMP9ALDH1A1HTTGHSR | |
| SCHEMBL2977278 | 0.91 | ALDH1A1 (0.72) | MMP2MMP9ALDH1A1HTTGHSR | |
| SCHEMBL31086908 | 0.87 | MMP2 (0.93) | MMP2MMP9GHSR | |
| SCHEMBL23519421 | 0.86 | ALDH1A1 (0.65) | MMP2MMP9ALDH1A1HTTGAA | |
| SCHEMBL6996 | 0.86 | ALDH1A1 (0.65) | MMP2MMP9ALDH1A1HTTGAA | |
| SCHEMBL6997 | 0.86 | ALDH1A1 (0.65) | MMP2MMP9ALDH1A1HTTGAA | |
| SCHEMBL6962263 | 0.85 | ALDH1A1 (0.72) | ALDH1A1HTTLMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144730-A1 | COMPOSITION FOR SKIN ANTI-AGING, SKIN BRIGHTENING OR SKIN REVERSE-AGING CONTAINING AMIDE-BASED COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2026-05-28 | — | — | US | disclosed |
| US-20260083715-A1 | COMPOSITION FOR ENHANCING IMMUNITY CONTAINING AMIDE-BASED COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2026-03-26 | — | — | US | disclosed |
| EP-4692062-A1 | NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME | Amorepacific Corporation (KR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024205303-A1 | NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME | (주)아모레퍼시픽 | 2024-10-03 | — | — | WO | disclosed |
| US-7160903-B2 | Sulfonylaminocarboxylic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-09 | — | — | US | disclosed |
| US-7160903-B2 | Sulfonylaminocarboxylic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-09 | — | — | US | disclosed |
| EP-0877018-B1 | Sulfonylaminocarboxylic acids | AVENTIS PHARMA GMBH (DE) | 2003-05-02 | — | — | EP | disclosed |
| WO-2001010837-A1 | MULTIVALENT SULFONAMIDES | THE PROCTER & GAMBLE COMPANY (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144730-A1 | COMPOSITION FOR SKIN ANTI-AGING, SKIN BRIGHTENING OR SKIN REVERSE-AGING CONTAINING AMIDE-BASED COMPOUND | TYR, ATG13, ARGLU1 | MMP2 694/4885MMP9 1269/4885ALDH1A1 1443/4885 |
| US-20260083715-A1 | COMPOSITION FOR ENHANCING IMMUNITY CONTAINING AMIDE-BASED COMPOUND | ARG1, MSR1, TLR1 | MMP2 1871/4885MMP9 3692/4885ALDH1A1 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.